BioLineRx and Hemispherian announce two GLIX1 presentations at the SNO Annual Meeting & Education Day (1.00a, 0.00)
BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day
BioLineRx registers 2.0M ADS (representing 1.21B ordinary shares) for resale by holder Armistice Capital - F-1 (1.00a, 0.00)
BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial (1.00a, 0.00)
BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)
Transcript Intelligence: BioLineRx Q2 Earnings Guidance
Transcript Intelligence: BioLineRx Q2 Earnings Themes
Transcript Intelligence: BioLineRx Q2 Earnings Q&A
BioLineRx reports Q2 EPS ($0.00) vs FactSet $0.00 [1 est] (2.00a, 0.00)
BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Powered by FactSet Research Systems Inc.